Harbour BioMed Appoints Raymond Zheng As Chief Business Officer

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, has appointed Dr. Raymond Zheng as Chief Business Officer (CBO).
 
Based in the United States, Zheng will lead global business development and alliance management functions, reporting directly to Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
 
In his new role, Zheng will seek to maximize the value of Harbour BioMed’s product portfolio through effective execution of the Company’s partnership initiatives. He will also play a key role in optimizing resources and coordinating business development operations globally to support the Company’s long-term strategic goals of investing in and developing transformative medicinal products to address key unmet medical needs.

Experience

Zheng was initially trained as a scientist and completed a research fellowship in the field of translational oncology at Harvard Medical School before joining the biopharmaceutical industry.
 
Prior to Harbour BioMed, Zheng served as founder and CSO of Urica Therapeutics, a clinical-stage company developing an oral therapy for refractory gout. During his tenure at Urica, early clinical development was completed, and the asset was subsequently acquired by a Newco backed by venture capital committed to supporting its pivotal development. He also made significant contributions as a business developer at Fortress Biotech and Agenus, where he managed value-added investments and negotiated transformative partnership transactions.
 
Zheng holds a Ph.D. in Cell and Molecular Biology from the University of California, Riverside, and an MBA in Finance from Rutgers University.
 
Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: “Raymond’s deep expertise in business development and strategic insights will be invaluable as we expand our collaborations and accelerate growth in key markets. We are thrilled to welcome him to the Harbour BioMed family and are confident that his leadership will significantly enhance the value of our portfolio.”
 
Zheng added: “I am honored to join Harbour BioMed and excited to work alongside a talented team committed to developing cutting-edge medicinal products. Harbour Mice is an industry-leading technology platform that has gained strong recognition worldwide. I look forward to leveraging my experience to foster robust partnerships that will drive the Company’s mission and enhance our global impact in the biopharmaceutical industry.”